Last reviewed · How we verify
Healive+Healive
Healive+Healive is a Combination vaccine Biologic drug developed by Sinovac Biotech Co., Ltd. It is currently FDA-approved for Prevention of hepatitis A infection, Prevention of hepatitis B infection. Also known as: Hepatitis A vaccine.
Healive+Healive is a hepatitis A and hepatitis B combination vaccine that stimulates the immune system to produce antibodies against both hepatitis A and B viruses.
Healive+Healive is a hepatitis A and hepatitis B combination vaccine that stimulates the immune system to produce antibodies against both hepatitis A and B viruses. Used for Prevention of hepatitis A infection, Prevention of hepatitis B infection.
At a glance
| Generic name | Healive+Healive |
|---|---|
| Also known as | Hepatitis A vaccine |
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | Combination vaccine |
| Target | Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This is an inactivated combination vaccine containing hepatitis A virus antigen and hepatitis B surface antigen (HBsAg). It works by presenting these antigens to the immune system, triggering the production of specific antibodies and cellular immunity against both viruses, thereby providing protection against infection with hepatitis A and B.
Approved indications
- Prevention of hepatitis A infection
- Prevention of hepatitis B infection
Common side effects
- Injection site pain or soreness
- Fever
- Fatigue
- Headache
Key clinical trials
- Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old (PHASE4)
- Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis B Vaccine (PHASE4)
- Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine (PHASE4)
- Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adults (PHASE4)
- Immunogenicity and Interchangeability of Two Inactivated Hepatitis A Vaccines (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Healive+Healive CI brief — competitive landscape report
- Healive+Healive updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI
Frequently asked questions about Healive+Healive
What is Healive+Healive?
How does Healive+Healive work?
What is Healive+Healive used for?
Who makes Healive+Healive?
Is Healive+Healive also known as anything else?
What drug class is Healive+Healive in?
What development phase is Healive+Healive in?
What are the side effects of Healive+Healive?
What does Healive+Healive target?
Related
- Drug class: All Combination vaccine drugs
- Target: All drugs targeting Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg)
- Manufacturer: Sinovac Biotech Co., Ltd — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of hepatitis A infection
- Indication: Drugs for Prevention of hepatitis B infection
- Also known as: Hepatitis A vaccine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing